Back

Usefulness of the baseline risk assessment guidelines to predict cancer therapy-related cardiac dysfunction in early-stage HER2 positive breast cancer

28 August 2023 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Cardiotoxicity of drugs and other therapies Cardiotoxicity of Drugs and Other Therapies ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Gerard Oristrell Santamaria

University Hospital Vall d'Hebron, Barcelona (Spain)

6 More presentations in this session

Presentation thumbnail
Pre-diabetes is associated with increased cardiac events in cancer patients prescribed anthracyclines
Doctor I. Cheang (Nanjing, CN)
Abstract Slides Video
Presentation thumbnail
Prognostic value of 6-minute walking test for early prediction of doxorubicin induced cardiotoxicity
Mrs G. Muckiene (Kaunas, LT)
Abstract Slides Video
Presentation thumbnail
CerS2 ko in vivo reduces pro-inflammatory ceramides and improves doxorubicin mediated cardiotoxicity
Doctor T. Kretzschmar (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Initial phase of anthracycline cardiotoxicity involves metabolic switch and activation of cardiac fibroblasts
Associate Professor K. Urbanek (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Effect of vitamin D receptor genetic polymorphism on the clinical response to angiotensin converting enzyme inhibitors therapy among breast cancer patients with chemotherapy induced cardiomyopathy
Miss I. Al-Ansary (Cairo, EG)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiotoxicity of drugs and other therapies

The Event

Event poster

ESC Congress 2023

28 August 2023 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Evaluation of the predictive value of the HFA-ICOS score for cardiotoxicity in breast cancer patients treated with anthracyclines and trastuzumab: a real-world observational study
thumbnail
Congress Presentation
Clinical application of the HFA/ICOS score in breast cancer women: its added value in the prediction of chemotherapy-related cardiac dysfunction
thumbnail
Congress Presentation
Validation of the HFA-ICOS risk assessment tool with real-world data from a prospective cohort of breast cancer patients in treatment with anthracyclines and trastuzumab

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources